Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osmolex ER for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT02153632Phase 3Terminated
- Start
- Jul 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of amantadine in levodopa-induced dyskinesia (LID). Started Jul 2014; status: terminated.
02
Drugs
amantadine
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT02153632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02153632.